ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Quantum Leap, this Phase 1 (open-label), multi-center study arm will investigate evorpacept, a CD47 blocker, in combination with ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody-drug conjugate, to determine the safety, tolerability and efficacy of this drug combination.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.79 USD | -1.53% |
|
-15.15% | -60.51% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.51% | 31Cr | |
+16.49% | 12TCr | |
+21.73% | 12TCr | |
+20.44% | 2.66TCr | |
-21.81% | 1.99TCr | |
-16.96% | 1.63TCr | |
-44.74% | 1.55TCr | |
-18.81% | 1.55TCr | |
+62.72% | 1.48TCr | |
+3.09% | 1.37TCr |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer